Skip to main content
Lyell Immunopharma, Inc. logo

Lyell Immunopharma, Inc. — Investor Relations & Filings

Ticker · LYEL ISIN · US55083R1041 US Manufacturing
Filings indexed 291 across all filing types
Latest filing 2026-04-24 Annual Report
Country US United States of America
Listing US LYEL

About Lyell Immunopharma, Inc.

https://lyell.com/

Lyell Immunopharma, Inc. is a clinical-stage cell therapy company that develops Chimeric Antigen Receptor (CAR) T-cell therapies for cancer. The company pioneers T-cell reprogramming technologies designed to overcome the primary barriers to durable clinical responses in patients. Its scientific approach focuses on enhancing T-cell function and fitness to improve the efficacy and persistence of its therapeutic candidates. Lyell's pipeline targets both solid tumors and hematologic malignancies, addressing significant unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
ARS - Lyell Immunopharma, Inc. (0001806952) (Filer)
Annual Report
2026-04-24 English
S-3 - Lyell Immunopharma, Inc. (0001806952) (Filer)
Registration Form
2026-04-03 English
4 Filing
Director's Dealing
2026-02-12 English
4 Filing
Director's Dealing
2026-02-12 English
4 Filing
Director's Dealing
2026-02-12 English
4 Filing
Director's Dealing
2026-02-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.